




RealRate

PHARMACEUTICAL 2021

Entasis Therapeutics Holdings Inc.
Rank 331 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Entasis Therapeutics Holdings Inc. Rank 331 of 409



The relative strengths and weaknesses of Entasis Therapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entasis Therapeutics Holdings Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Entasis Therapeutics Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 275% points.

The company's Economic Capital Ratio, given in the ranking table, is -416%, being 62% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	60,132
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,565
Liabilities, Non-Current	704
Other Assets	1,204
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	222
Research and Development	41,022
Revenues	3,735
Selling, General and Administrative Expense	13,209

Output Variable	Value in 1000 USD
Assets	61,558
Liabilities	9,269
Expenses	54,231
Stockholders Equity	52,289
Net Income	-50,496
Comprehensive Net Income	-50,496
Economic Capital Ratio	-416%

